CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company’s nucleotide prodrug, IDX21437, and for samatasvir, Idenix’s once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress™ 2014, the 49th annual meeting of the European Association for the Study of the Liver (EASL), taking place in London, April 9-13, 2014. Full abstracts can now be viewed at the EASL Congress website.
Help employers find you! Check out all the jobs and post your resume.
